articl
present
overview
import
respiratori
virus
except
influenza
viru
cover
separ
articl
overview
includ
descript
agent
epidemiolog
pathogenesi
clinic
featur
manag
control
virus
cover
respiratori
syncyti
viru
parainfluenza
virus
metapneumoviru
coronavirus
includ
agent
sar
respiratori
adenovirus
rhinoviru
bocaviru
respiratori
virus
frequent
caus
agent
diseas
human
signific
impact
morbid
mortal
worldwid
mainli
children
approxim
onefifth
childhood
death
worldwid
relat
acut
respiratori
infect
ari
particularli
impoverish
popul
tropic
region
ari
casetofat
ratio
remark
higher
temper
region
world
eight
human
respiratori
virus
circul
commonli
age
group
recogn
adapt
effici
persontoperson
transmiss
tabl
addit
sar
coronaviru
sarscov
avian
influenza
viru
emerg
recent
year
threat
public
health
sarscov
circul
sinc
avian
influenza
viru
caus
limit
outbreak
human
infect
current
known
respiratori
virus
still
account
clinic
relev
human
viral
respiratori
ill
systemat
search
new
agent
use
molecular
tool
expect
discov
previous
unidentifi
agent
although
respiratori
virus
caus
great
burden
diseas
prevent
therapeut
intervent
current
avail
howev
recent
advanc
molecular
cell
biolog
respiratori
virus
hope
result
develop
use
intervent
articl
focu
common
respiratori
virus
except
influenza
viru
cover
separ
articl
agent
human
respiratori
syncyti
viru
hrsv
known
human
pathogen
genu
pneumoviru
famili
paramyxovirida
first
isol
chimpanze
coryza
one
year
later
agent
recov
two
children
respiratori
ill
hrsv
virion
heterogen
size
shape
consist
helic
nucleocapsid
contain
nt
negativesens
singlestrand
rna
tightli
bound
nucleoprotein
n
viru
particl
surround
lipid
bilay
contain
glycoprotein
g
receptor
bind
f
membran
fusion
sh
unknown
function
virion
also
contain
rnadepend
rna
polymeras
l
phosphoprotein
p
protein
figur
addit
three
nonstructur
protein
produc
infect
cell
two
hrsv
group
b
origin
distinguish
base
antigen
differ
attach
glycoprotein
g
later
separ
confirm
gene
phylogenet
analysi
g
gene
sequenc
allow
divis
group
hrsv
genotyp
new
genotyp
continu
emerg
other
circul
previous
tend
disappear
hrsv
bind
cell
surfac
glycosaminoglycan
viral
glycoprotein
g
although
g
proteinindepend
bind
also
exist
upon
virusreceptor
interact
fusion
viru
cell
membran
take
place
bind
viral
protein
f
cell
gtpase
rhoa
hrsv
intern
consid
phindepend
may
happen
either
plasma
endosom
membran
express
viral
protein
f
plasma
membran
infect
cell
promot
fusion
adjac
cell
result
format
syncytia
hallmark
paramyxoviru
cytopath
effect
cytoplasm
negativestrand
viral
rna
transcrib
coordin
action
protein
l
n
p
result
set
mrna
direct
synthesi
viral
protein
transcript
mrna
occur
gradient
decreas
amount
transcript
gener
end
end
genom
templat
figur
point
polymeras
complex
switch
mrna
transcript
viralrna
replic
gener
fulllength
rna
polar
opposit
genom
antigenom
antigenom
serv
templat
polymeras
complex
gener
negativesens
rna
genom
progeni
viral
protein
seem
alter
polymeras
complex
way
may
direct
prefer
replic
transcript
viral
matrix
protein
mediat
associ
nucleocapsid
lipid
raft
contain
hrsv
envelop
protein
plasma
membran
give
rise
viru
bud
viral
protein
suppressor
type
interferon
induct
hrsv
singl
frequent
caus
lower
respiratori
tract
infect
lrti
lead
morbid
mortal
children
worldwid
children
infect
hrsv
age
reinfect
common
throughout
life
annual
season
outbreak
hrsv
occur
winterearli
spring
temper
region
raini
season
tropic
area
like
increas
indoor
crowd
one
genotyp
hrsv
group
b
cocircul
season
outbreak
group
predomin
chang
year
year
appar
correl
group
genotyp
clinic
manifest
diseas
sever
hrsv
transmiss
requir
close
contact
either
larg
particl
aerosol
contamin
hand
follow
inocul
eye
nose
secondari
infect
famili
contact
index
case
common
estim
infant
hrsv
infect
requir
medic
attent
hospit
approxim
children
bronchiol
first
year
life
caus
hrsv
certain
region
lrti
caus
hrsv
respons
hospit
infant
season
outbreak
known
hrsv
evolut
base
phylogenet
studi
g
protein
gene
quit
variabl
among
clinic
isol
rate
accumul
nucleotid
substitut
gene
calcul
substitut
per
site
per
year
respect
hrsv
b
steadi
accumul
amino
acid
chang
time
lead
emerg
new
lineag
therefor
hrsv
genotyp
predomin
outbreak
tend
replac
other
subsequ
year
like
develop
herd
immun
toward
immunodomin
epitop
mutant
hrsv
b
contain
amino
acid
redupl
variabl
region
g
protein
ectodomain
recent
identifi
made
possibl
track
dissemin
novel
hrsv
strain
insert
first
detect
argentina
isol
follow
year
belgium
unit
kingdom
japan
north
america
indic
new
hrsv
strain
spread
rapidli
worldwid
remark
period
year
new
variant
becam
predomin
hrsv
b
strain
accumul
variat
g
gene
hrsv
replic
respiratori
epithelia
reach
high
titer
nasal
secret
caus
viru
shed
week
end
symptom
celltocel
spread
lead
involv
entir
respiratori
tree
hrsv
reach
bronchiol
day
onset
symptom
induc
necrosi
ciliat
cell
syncytia
format
peribronchiolar
inflamm
abund
lymphocyt
macrophag
impair
secret
clearanc
result
small
airway
obstruct
lung
hyperinfl
typic
bronchiol
hrsv
pneumonia
interstiti
mononuclear
infiltr
eosinophil
cytoplasm
inclus
epitheli
cell
multinucl
giant
cell
frequent
coexist
bronchiol
hrsv
diseas
particularli
sever
young
babi
whose
immatur
airway
unabl
compens
virusinduc
damag
natur
acquir
immun
rsv
incomplet
shortliv
diseas
sever
reduc
reinfect
secretori
iga
correl
better
protect
serum
antibodi
level
patient
age
preexist
hrsvspecif
matern
antibodi
influenc
develop
diseas
cellmedi
immun
respons
central
recoveri
infect
immunosuppress
patient
risk
sever
hrsv
diseas
fatal
outcom
type
immun
respons
hrsv
major
factor
develop
wheez
asthma
exacerb
deviat
toward
cytokin
respons
associ
sever
diseas
wherea
respons
lead
effect
viral
clearanc
milder
ill
preexist
defici
may
associ
sever
diseas
children
may
marker
predisposit
wheez
asthma
later
life
hrsv
g
protein
produc
membraneanchor
solubl
form
type
ii
glycoprotein
two
highli
variabl
extracellular
mucinlik
domain
separ
cysteinerich
much
conserv
central
region
inhibit
innat
immun
modul
cytokin
product
hrsv
infect
epitheli
cell
trigger
releas
cytokin
ifn
cytokin
ifn
ifn
chemokin
amplifi
immun
respons
inflammatori
reaction
children
vaccin
formalininactiv
hrsv
vaccin
sever
diseas
expos
natur
infect
appar
due
imbal
protect
immunopatholog
tcell
respons
elicit
vaccin
would
favor
pattern
upon
subsequ
hrsv
infect
wherea
previou
natur
infect
would
favor
pattern
respons
reinfect
follow
day
incub
period
hrsv
infect
caus
ill
rang
mild
upper
respiratori
infect
uri
sever
lower
respiratori
infect
lri
includ
pneumonia
bronchiol
tracheobronch
croup
infant
young
children
uri
frequent
accompani
otiti
media
fever
frequent
manifest
lri
due
hrsv
infant
bronchiol
usual
preced
day
symptom
upper
respiratori
tract
character
tachypnea
dyspnea
cough
expiratori
wheez
air
trap
sever
case
intercost
muscl
retract
cyanosi
fever
present
infant
lung
hyperaer
sometim
segment
atelectasi
chest
xray
blood
count
usual
show
lymphocytosi
increas
neutrophil
associ
bacteri
superinfect
acut
otiti
media
found
children
bronchiol
patient
underli
condit
congenit
heart
diseas
prematur
cystic
fibrosi
bronchopulmonari
dysplasia
well
immunocompromis
host
age
risk
sever
fatal
hrsv
infect
children
year
age
adult
hrsv
ill
usual
mild
moder
upper
respiratori
tract
symptom
includ
coryza
cough
sore
throat
hoars
often
accompani
lowgrad
fever
exacerb
chronic
pulmonari
diseas
wheez
seen
adult
hrsv
sever
pneumonia
also
occur
particularli
elderli
role
hrsv
infect
wheez
asthma
exacerb
infant
especi
famili
histori
allergi
establish
studi
sever
differ
part
world
includ
temper
well
tropic
region
elderli
hrsv
infect
lower
respiratori
tract
lrt
mainli
character
interstiti
pneumonia
prolong
cough
dyspnea
person
chronic
pulmonari
condit
hrsv
consid
differenti
diagnosi
flulik
ill
nasopharyng
aspir
nasal
wash
swab
well
lrt
sampl
use
specimen
hrsv
detect
sampl
storag
freezethaw
significantli
reduc
hrsv
recoveri
cultur
hrsv
isol
sever
human
cell
line
hela
syncytia
format
note
cell
day
rapid
hrsv
antigen
detect
method
includ
immunofluoresc
slough
respiratori
cell
eia
membranebas
chromatographi
sensit
specif
commerci
avail
pointofcar
simpl
test
requir
equip
ideal
emerg
room
primari
care
hrsv
diagnosi
detect
hrsv
rna
rtpcr
convent
base
realtim
techniqu
becom
wide
accept
sensit
diagnost
assay
addit
sensit
qualit
result
realtim
method
applic
quantit
viral
load
could
simultan
detect
subtyp
rsv
directli
clinic
specimen
amplif
method
base
pcr
nasba
becom
commerci
avail
hrsv
diagnosi
hrsv
serolog
limit
valu
case
manag
may
use
epidemiolog
survey
hrsv
uri
requir
specif
treatment
antibiot
may
consid
presenc
bacteri
complic
acut
otiti
media
infant
hrsv
bronchiol
support
treatment
consist
bronchodil
prevent
hypoxemia
electrolyt
imbal
measur
prevent
hypoxemia
may
vari
simpl
aspir
respiratori
secret
mechan
ventilatori
support
even
extracorpor
membran
oxygen
ecmo
antivir
drug
current
approv
treatment
infant
hrsv
synthet
nucleosid
ribavirin
deliv
smallparticl
aerosol
via
mist
tent
mask
oxygen
hood
ventil
although
ribavirin
trial
lack
power
provid
definit
recommend
antivir
recommend
infant
young
children
underli
condit
congenit
heart
diseas
cystic
fibrosi
immunosuppress
therapi
also
consid
prematur
babi
infant
younger
week
age
sever
ill
ribavirin
therapi
may
reduc
durat
hospit
stay
requir
mechan
ventil
consid
chemokinereceptor
system
central
inflammatori
cell
recruit
hrsv
bronchiol
effect
chemokin
receptor
blocker
develop
may
also
becom
use
reduc
inflamm
diseas
sever
vaccin
current
licens
hrsv
prophylaxi
diseas
enhanc
relat
bia
caus
formalininactiv
vaccin
significantli
slow
progress
toward
hrsv
vaccin
immun
respons
natur
acquir
hrsv
poor
develop
effect
vaccin
face
challeng
improv
natur
infect
elicit
balanc
immun
respons
includ
cell
cell
hope
hrsvneutral
antibodi
includ
secretori
iga
intranas
deliv
genet
engin
attenu
vector
vaccin
promis
altern
newborn
wherea
subunit
vaccin
candid
combin
adjuv
promot
protect
respons
could
altern
previous
expos
children
passiv
immun
highrisk
infant
monthli
applic
hrsv
immunoglobulin
season
outbreak
reduc
incid
sever
hrsv
infect
highrisk
children
costli
intervent
avail
mean
protect
highrisk
children
seriou
hrsv
diseas
monthli
intramuscular
inject
human
monoclon
antibodi
palivizumab
consid
passiv
immunoprophylaxi
hrsv
season
highrisk
infant
preterm
babi
less
month
old
children
congenit
heart
diseas
children
less
year
age
bronchopulmonari
dysplasia
secondgener
mab
motavizumab
increas
affin
phase
iii
clinic
trial
write
thirdgener
mab
numaxyt
develop
increas
antibodi
serum
halflif
thu
obviat
need
monthli
dose
hospit
infant
rsv
infect
isol
group
prevent
nosocomi
crossinfect
hand
wash
use
eyenos
goggl
gown
glove
decontamin
surfac
fomit
addit
control
measur
agent
human
parainfluenza
virus
hpiv
frequent
caus
lrti
infant
children
worldwid
hpiv
share
structur
biolog
characterist
hrsv
distribut
two
genera
famili
paramyxovirida
hpiv
classifi
antigen
type
subtyp
b
hpiv
type
classifi
genu
respiroviru
wherea
hpiv
type
genu
rubulaviru
virion
pleomorph
singlestrand
negativesens
rna
rang
nm
diamet
figur
glycoprotein
hn
hemagglutinin
neuraminidas
activ
promot
viruscel
attach
bind
sialic
acid
present
cell
surfac
protein
upon
cleavag
proteolyt
enzym
viral
protein
f
mediat
fusion
viral
cell
membran
consequ
releas
nucleocapsid
cytoplasm
viru
life
cycl
occur
way
similar
paramyxovirida
figur
nonstructur
protein
equival
hrsv
present
hpiv
hpiv
zincbind
protein
v
found
high
intracellular
level
littl
quantiti
viral
particl
play
role
control
viralrna
synthesi
counteract
host
cell
interferon
type
respons
primari
hpiv
infect
occur
earli
childhood
age
virtual
children
seroposit
reinfect
frequent
diseas
sever
reinfect
invers
proport
titer
serumneutr
antibodi
elicit
previou
infect
type
frequent
associ
lri
children
immunocompromis
chronic
ill
elderli
wherea
caus
mostli
uri
children
adult
temper
region
hemispher
caus
outbreak
fall
altern
year
either
alon
cocircul
caus
spring
summer
outbreak
temper
area
circul
endem
throughout
year
especi
immunocompromis
chronic
ill
wherea
occur
sporad
throughout
year
children
adult
tropic
region
higher
hpiv
activ
occur
raini
season
hpiv
spread
mainli
within
famili
close
commun
nurseri
day
care
center
pediatr
ward
high
secondari
attack
rate
viru
persist
long
environ
transmit
mainli
larg
droplet
fomit
viral
shed
usual
last
day
prolong
shed
month
report
young
children
immunosuppress
host
rate
hpiv
infect
infant
similar
hrsv
hpiv
caus
less
hospit
hrsv
hpiv
replic
ciliat
cell
caus
cytolysi
respiratori
mucosa
infect
begin
upper
respiratori
tract
dissemin
respiratori
tree
larynx
trachea
mostli
involv
croup
syndrom
extens
involv
lower
respiratori
tree
may
present
tracheobronch
bronchopneumonia
bronchiol
similar
occur
hrsv
amplifi
inflammatori
respons
induc
viral
infect
epitheli
cell
caus
mononuclear
interstiti
infiltr
epitheli
necrosi
inflammatori
exud
alveoli
hyalin
membran
format
lung
case
croup
mononuclear
inflammatori
cell
infiltr
seen
subglot
area
host
immun
larg
mediat
antibodi
two
surfac
protein
hn
f
secretori
antibodi
best
marker
protect
hpiv
howev
protect
limit
reinfect
frequent
tcell
immun
respons
involv
clearanc
viru
immunocompromis
host
may
develop
progress
even
lethal
diseas
addit
host
immun
respons
factor
inher
viru
may
central
pathogen
vari
suscept
hpiv
f
protein
cleavag
proteolyt
enzym
present
infect
tissu
day
incub
period
patient
hpiv
infect
may
develop
rhiniti
pharyng
laryngotracheobronch
croup
bronchiol
pneumonia
approxim
twothird
hpiv
infect
children
result
febril
uri
associ
otiti
media
case
remain
onethird
hpiv
infect
caus
croup
bronchiol
pneumonia
hpiv
bronchopneumonia
bronchiol
usual
less
sever
caus
hrsv
caus
case
croup
strike
clinic
present
hpiv
infect
commonli
seen
children
younger
year
bark
brassi
cough
dysphonia
inspiratori
stridor
suprastern
retract
due
subglot
edema
cardin
featur
children
recov
day
may
develop
bronchopneumoniacroup
syndrom
less
common
manifest
apnea
sudden
infant
death
syndrom
parot
myopericard
suggest
certain
hpiv
strain
may
becom
neuroinvas
sinc
immun
hpiv
incomplet
reinfect
occur
throughout
life
adult
hpiv
infect
gener
nonspecif
uri
commonli
hoars
hpiv
caus
particularli
sever
diseas
immunocompromis
host
especi
children
sever
combin
immunodefici
interferondefici
patient
chemotherapi
bone
marrow
solid
organ
transplant
recipi
mortal
bone
marrow
transplant
patient
hpiv
infect
reach
hpiv
present
respiratori
secret
day
onset
symptom
isol
nasopharyng
washesaspir
swab
bronchoalveolar
lavag
cultur
monkey
kidney
primari
cell
sever
continu
cell
line
vero
mdck
bhk
hela
presenc
hpiv
monolay
confirm
hemadsorpt
guinea
pig
erythrocyt
immunofluoresc
isol
hpiv
shell
vial
assay
format
produc
mix
result
hpiv
exfoli
respiratori
epitheli
cell
use
decad
sensit
moder
low
sensit
assay
detect
hpiv
rna
rtpcr
includ
multiplex
format
realtim
pcrbase
test
becom
wide
accept
serolog
assay
hpiv
igm
igg
highli
specif
use
acut
patient
manag
present
support
symptomat
treatment
avail
hpiv
infect
patient
croup
nebul
racem
epinephrin
budesonid
rapid
effect
shortterm
highdos
system
corticosteroid
may
reduc
need
intub
besid
anecdot
report
aerosol
ribavirin
treatment
immunocompromis
patient
hpiv
lrt
infect
specif
antivir
treatment
licens
hpiv
inhibitor
protein
hn
effect
vitro
anim
model
reach
clinic
use
vaccin
current
avail
prevent
hpiv
infect
earli
trial
inactiv
hpiv
vaccin
unsuccess
revers
genet
provid
mean
identifi
basi
attenu
vaccin
candid
live
attenu
coldadapt
vaccin
immunogen
children
still
hold
promis
clinic
applic
also
candid
vaccin
use
murin
sendai
viru
express
f
hn
protein
elicit
neutral
antibodi
ifnproduct
cotton
rat
protect
challeng
encourag
develop
futur
human
use
case
hrsv
infect
hand
wash
use
eyenos
goggl
gown
glove
well
decontamin
fomit
use
prevent
nosocomi
spread
hpiv
agent
human
metapneumoviru
hmpv
recogn
frequent
caus
communityacquir
ari
children
adult
worldwid
agent
discov
netherland
studi
previous
unidentifi
viral
isol
induc
cpe
cultur
cell
viral
isol
recov
respiratori
secret
children
ari
occur
winter
time
period
year
electron
microscopi
cell
cultur
show
cpe
reveal
paramyxoviruslik
particl
sequenc
randomli
prime
pcr
product
reveal
genom
sequenc
organ
consist
paramyxoviru
subfamili
pneumovirina
relat
avian
pneumoviru
genu
metapneumoviru
rather
avian
viru
infect
human
new
agent
primari
human
pathogen
screen
bank
serum
sampl
hmpv
antibodi
netherland
indic
viru
circul
least
decad
hmpv
particl
envelop
pleomorph
spheric
filament
particl
nm
diamet
like
paramyxovirus
hmpv
negativesens
singlestrand
rna
genom
viral
replic
occur
gradient
manner
complet
genom
sequenc
reveal
contrast
pneumovirus
hmpv
differ
posit
gene
l
lack
gene
similar
hrsv
hmpv
gene
g
sh
essenti
viru
replic
protein
appear
control
switch
transcript
replic
remov
gene
lead
accumul
viral
mrna
attenu
viral
replic
genet
antigen
studi
indic
similar
hrsv
hmpv
isol
cluster
two
main
genet
subgroup
b
similar
f
gene
sequenc
subgroup
includ
least
two
genogroup
contrast
g
protein
gene
sequenc
conserv
subgroup
appar
correl
subgroup
diseas
sever
temper
climat
hmpv
circul
predominantli
late
winter
spring
peak
activ
close
follow
overlap
hrsv
differ
strain
subgroup
b
cocircul
outbreak
vari
locat
locat
year
year
age
year
children
antibodi
hmpv
seropreval
among
adult
virtual
although
incid
hmpv
diseas
may
vari
significantli
year
year
one
locat
agent
gener
detect
sampl
ari
patient
note
percentag
much
higher
peak
month
reach
studi
peak
age
hospit
hmpv
month
male
seem
greater
risk
lrt
involv
hmpv
rare
detect
sampl
asymptomat
patient
associ
adult
ari
mainli
elderli
debilit
underli
condit
littl
known
hmpvspecif
mechan
pathogenesi
anim
studi
show
disrupt
respiratori
epithelium
epitheli
cell
slough
inflammatori
infiltr
lung
patholog
studi
human
underli
diseas
hmpv
infect
main
find
acut
organ
lung
injuri
diffus
alveolar
damag
slough
epitheli
cell
eosinophil
cytoplasm
inclus
multinucl
giant
cell
histiocyt
hyalin
membran
format
clinic
hmpv
infect
close
resembl
caus
hrsv
rang
mild
upper
ari
sever
bronchiol
pneumonia
children
age
group
risk
hrsv
howev
median
age
children
hospit
hmpv
infect
greater
children
hrsv
hmpv
consid
second
hrsv
caus
bronchiol
chest
xray
reveal
infiltr
hyperinfl
peribronchi
cuf
frequent
symptom
hmpv
infect
fever
tachypnea
dyspnea
cough
hypoxia
wheez
stridor
rhiniti
sore
throat
otiti
media
frequent
present
hrsv
hospit
infant
young
children
may
requir
intens
care
mechan
ventil
coinfect
hmpv
appear
increas
likelihood
sever
hrsv
diseas
tenfold
addit
lrti
hmpv
also
caus
upper
respiratori
symptom
indistinguish
caus
common
respiratori
virus
hmpv
may
caus
seriou
infect
patient
comorbid
immunosuppress
condit
well
young
elderli
one
studi
individu
older
lrti
caus
hmpv
least
one
underli
chronic
debilit
condit
includ
lymphoma
leukemia
neurolog
cardiovascular
diseas
hmpv
recogn
frequent
caus
acut
wheez
children
studi
found
children
hmpv
brazil
wheez
chest
indraw
convers
wheez
children
finland
hmpv
addit
previou
histori
asthma
frequent
associ
hmpv
hrsv
hmpvinfect
patient
often
treat
bronchodil
corticosteroid
hrsvinfect
patient
hmpv
isol
nasopharyng
washesaspir
cell
medium
contain
trypsin
viru
grow
poorli
cytopath
effect
characterist
neg
hemadsorpt
test
develop
usual
late
inocul
day
rtpcr
current
wide
adopt
method
hmpv
detect
primer
set
target
n
l
gene
report
sensit
detect
hmpv
genet
group
realtim
pcr
assay
hmpv
becom
gold
standard
sensit
convent
rtpcr
report
circul
strain
hmpv
genet
distinct
four
alreadi
identifi
lineag
detect
rtpcr
primer
n
gene
strain
becom
widespread
primer
set
rtpcr
may
modifi
hmpvspecif
antibodi
develop
commerci
hmpv
immunofluoresc
assay
method
sensit
realtim
rtpcr
readili
applic
diagnost
laboratori
respiratori
virus
routin
done
support
measur
oxygen
therapi
bronchodil
corticosteroid
mechan
ventil
specif
antivir
treatment
hmpv
ribavirin
inhibitori
hmpv
vitro
although
hmpv
vaccin
avail
time
demonstr
hamster
ferret
african
green
monkey
suscept
infect
hamster
vaccin
hmpv
protect
challeng
hmpv
b
genet
group
open
possibl
hmpv
vaccin
design
human
neutral
monoclon
antibodi
f
protein
activ
experiment
infect
anim
like
becom
avail
prophylaxi
hmpv
futur
agent
human
rhinovirus
hrv
frequent
respiratori
pathogen
human
commonli
detect
virus
sampl
common
cold
suffer
hrv
small
nonenvelop
positivestrand
rna
virus
famili
picornavirida
genu
rhinoviru
distribut
two
speci
serotyp
b
serotyp
recent
describ
new
strain
contain
delet
region
may
constitut
new
speci
c
hrv
atom
structur
solv
reveal
icosahedr
particl
compos
pentam
diamet
nm
figur
surround
fivefold
vertex
capsid
protein
adjac
pentam
nm
wide
canyon
contain
receptor
bind
site
hrv
major
receptor
group
hrv
genom
kb
monocistron
singlestrand
uncap
rna
small
genom
protein
vpg
coval
link
end
poli
tail
end
first
nt
end
constitut
highli
structur
untransl
region
utr
intern
ribosom
entri
site
ire
permit
initi
translat
follow
receptor
bind
viral
positivestrand
rna
releas
cytoplasm
translat
singl
orf
produc
one
polyprotein
cleav
cotransl
gener
three
precursor
origin
capsid
protein
origin
nonstructur
protein
vpg
cleavag
precursor
gener
endproduct
last
cleavag
occur
final
stage
viru
matur
figur
one
cleavag
product
rnabas
rna
polymeras
produc
negativestrand
fulllength
copi
genom
use
templat
product
expand
pool
positivestrand
rna
positivestrand
rna
either
translat
viral
protein
packag
genom
newli
assembl
virion
hrv
replic
cycl
take
place
associ
vesicl
membran
cytoplasm
matur
virion
releas
upon
cell
lysi
figur
recent
recogn
hrv
serotyp
classifi
accord
receptor
specif
three
group
major
group
serotyp
whose
receptor
intercellular
adhes
minor
group
serotyp
whose
receptor
lowdens
lipoprotein
receptor
ldlr
share
properti
human
enteroviru
util
sialic
acid
residu
cell
protein
receptor
rang
hrv
serotyp
speci
current
accept
classif
system
base
sequenc
phylogenet
comparison
rather
receptor
usag
antivir
suscept
expect
expand
sequenc
inform
obtain
field
strain
fact
new
genet
clade
recent
detect
hong
kong
consist
strain
associ
mostli
lrti
children
wheez
contain
import
delet
region
probabl
repres
new
speci
hrv
name
hrv
c
hrv
stabl
day
environment
surfac
resist
ethanol
ether
chloroform
nonion
deterg
sensit
uv
light
ph
lower
halogen
chlorin
bromin
iodin
phenol
disinfect
hrv
predomin
agent
ari
world
infect
occur
peopl
contin
includ
remot
locat
popul
group
bushmen
kalahari
desert
nativ
alaskan
isol
amazon
indian
tribe
rhinovirus
clearli
shown
frequent
caus
cold
unit
state
western
europ
frequent
associ
ari
children
throughout
world
hrv
estim
caus
autumn
cold
adult
unit
state
around
respiratori
infect
ambulatori
children
tropic
area
evid
suggest
indoor
hrv
transmiss
favor
high
rel
humid
crowd
young
children
occur
unit
state
begin
school
term
may
explain
autumn
season
peak
hrv
tropic
region
howev
rel
humid
remain
reach
raini
season
longitudin
studi
found
obviou
hrv
season
hrv
transmiss
requir
close
exposur
occur
mainli
handtohand
contact
follow
selfinocul
eye
nose
also
happen
airborn
spread
hrv
reach
nasal
caviti
infect
occur
virtual
suscept
subject
approxim
infect
develop
ill
day
incub
children
play
central
role
spread
viru
household
hrv
replic
restrict
respiratori
epithelium
take
place
scatter
ciliat
cell
nose
noncili
cell
nasopharynx
tropism
seem
consequ
receptor
avail
infect
limit
number
cell
trigger
nuclear
transloc
nfb
gene
express
cytokin
chemokin
inflammatori
mediat
associ
stimul
local
parasympathet
nerv
end
result
develop
cold
symptom
kinin
prostaglandin
proinflammatori
cytokin
chemokin
may
contribut
vasodil
increas
vascular
permeabl
influx
polymorphonuclear
leukocyt
exocrin
gland
secret
nerv
end
stimul
result
nasal
obstruct
rhinorrhea
sneez
cough
sore
throat
serotypespecif
neutral
igm
igg
iga
antibodi
develop
infect
person
day
persist
year
protect
infect
partial
attribut
presenc
iga
antibodi
nasal
secret
recoveri
ill
depend
cellmedi
immun
hrvinduc
blastogenesi
natur
killer
cell
activ
mitogenstimul
cell
product
ifnhav
document
hrv
infect
hrv
induc
express
human
defensin
respiratori
epithelium
support
role
host
defens
agent
hrvinduc
cold
clinic
indistinguish
cold
viral
etiolog
main
symptom
nasal
discharg
nasal
obstruct
sneez
sore
scratchi
throat
hoars
cough
headach
facial
ear
pressur
may
present
fever
malais
uncommon
symptom
last
approxim
day
may
persist
week
case
infant
toddler
may
display
nasal
discharg
otherwis
asymptomat
clear
associ
distinct
clinic
outcom
particular
serotyp
speci
hrv
major
patient
obstruct
mucos
abnorm
sinu
caviti
eustachian
tube
middl
ear
predispos
secondari
bacteri
sinus
otiti
media
hrv
rna
may
detect
rtpcr
maxillari
sinu
brush
adult
present
acut
sinus
sampl
middl
ear
fluid
children
less
year
age
diagnosi
acut
otiti
media
hrv
frequent
associ
exacerb
chronic
obstruct
pulmonari
diseas
asthma
attack
children
year
age
adult
addit
cold
hrv
increasingli
recogn
major
caus
lrti
children
immunocompromis
host
detect
time
often
hrsv
associ
wheez
first
year
life
major
recent
advanc
hrv
research
develop
experiment
anim
model
infect
use
ldlrbind
minor
serotyp
balbc
mice
bind
major
serotyp
human
transgen
mice
model
boost
research
pathogenesi
antivir
therapi
hrv
detect
respiratori
secret
isol
cultur
suscept
cell
line
cell
line
primat
origin
support
hrv
propag
certain
strain
hela
cell
human
embryon
fibroblast
provid
higher
sensit
hrv
isol
clinic
specimen
hrv
shed
peak
around
h
infect
declin
rapidli
may
remain
low
level
week
optim
growth
temperatur
hrv
c
roller
drum
cultur
examin
day
presenc
hrv
indic
typic
cpe
confirm
acid
sensit
isol
unlik
picornavirus
hrv
acidlabil
properti
distinguish
enterovirus
rapid
assay
hrv
detect
like
immunofluoresc
antigen
detect
method
avail
larg
number
serotyp
homotyp
natur
hrv
antibodi
restrict
serolog
experiment
set
rtpcr
clinic
sampl
sensit
method
hrv
detect
realtim
pcrbase
assay
develop
sever
laboratori
use
mostli
primer
direct
conserv
genom
potenti
detect
serotyp
hrv
speci
realtim
pcr
multiplex
assay
direct
conserv
sequenc
differ
viral
speci
genera
well
recent
develop
method
multicodeplx
masstag
detect
sever
viral
pathogen
singl
run
expect
becom
method
choic
largescal
sampl
test
near
futur
sever
trial
antivir
agent
hrv
conduct
specif
treatment
licens
mainli
lack
potenc
untoward
side
effect
drug
deliveri
problem
symptomat
treatment
done
varieti
nonprescript
medic
system
sympathomimet
decongest
may
reduc
nasal
obstruct
firstgener
antihistamin
may
reduc
sneez
rhinorrhea
nonsteroid
antiinflammatori
drug
may
reduc
headach
cough
system
symptom
larg
number
hrv
serotyp
minim
crossantigen
hamper
develop
hrv
vaccin
may
possibl
reduc
exposur
hrv
hand
wash
contact
cold
suffer
handl
object
may
contamin
respiratori
secret
applic
virucid
agent
salicyl
acid
pyroglutam
acid
hand
reduc
recoveri
rhinoviru
hand
skin
treat
person
shortterm
postexposur
prophylaxi
intranas
ifnsignificantli
reduc
incid
hrv
cold
household
contact
index
case
howev
cost
local
side
effect
associ
difficulti
make
drug
avail
home
time
fashion
reduc
util
approach
adenovirus
nonenvelop
icosahedr
dna
virus
genu
mastadenoviru
famili
adenovirida
adenoviru
capsid
consist
three
morpholog
antigen
function
distinct
type
capsomer
hexon
penton
base
penton
fiber
project
penton
base
figur
hexon
penton
base
contain
complement
fix
groupspecif
antigen
common
human
adenovirus
wherea
fiber
primarili
neutral
hemagglutinationinhibit
typespecif
antigen
serum
neutral
permit
classif
human
adenovirus
distinct
serotyp
distribut
six
speci
af
adenovirus
commonli
accompani
small
singlestrand
dna
parvovirus
known
adenoassoci
virus
seem
caus
specif
diseas
fiber
protein
bind
host
cell
protein
coxsacki
b
adenoviru
receptor
car
protein
immunoglobulin
superfamili
serv
highaffin
receptor
attach
adenoviru
speci
c
e
f
plasma
membran
protein
ligand
fiber
adenoviru
speci
b
follow
fiberreceptor
bind
interact
penton
base
cell
surfac
integrin
trigger
endocytosi
exposur
viru
cytosol
microtubulemedi
transport
nucleu
final
disassembl
nuclear
pore
nucleu
set
earli
mrna
transcrib
direct
translat
protein
modul
cell
cycl
block
apoptosi
shut
host
mrna
transport
nucleu
dna
replic
late
mrna
transcrib
product
includ
viral
structur
protein
viru
assembl
take
place
nucleu
infecti
cycl
complet
releas
million
virion
upon
cell
lysi
figur
figur
adenoviru
replic
cycl
viru
bind
receptor
car
coxsacki
b
adenoviru
receptor
integrin
adsorpt
viru
intern
receptormedi
endocytosi
direct
nuclear
pore
final
disassembl
occur
viral
dna
genom
releas
nucleu
earli
set
gene
express
earli
viral
gene
product
mediat
viral
gene
express
dna
replic
late
viral
gene
express
gener
structur
protein
assembl
progeni
virion
occur
new
virus
releas
cell
lysi
adenovirus
stabl
wide
ph
rang
resist
isopropyl
alcohol
ether
chloroform
stabl
week
room
temperatur
year
approxim
c
colder
even
lyophil
inactiv
sodium
hypochlorit
exposur
c
min
respiratori
diseas
among
frequent
manifest
infect
adenovirus
particularli
children
age
year
respiratori
infect
adenovirus
occur
worldwid
appar
season
outbreak
occur
especi
crowd
condit
frequent
late
winter
spring
earli
summer
common
serotyp
associ
respiratori
diseas
serotyp
adenoviru
lownumb
serotyp
frequent
age
year
account
case
uri
approxim
case
lri
children
adult
adenovirus
occur
sporad
caus
mostli
uri
infect
adenovirus
type
usual
epidem
attack
rate
per
week
newli
assembl
militari
recruit
whose
adenoviru
carriag
rate
may
high
group
adenovir
syndrom
vari
mild
cold
sever
lri
overal
attack
rate
may
reach
individu
need
hospit
tropic
area
incid
adenoviru
infect
militari
recruit
lower
differ
serotyp
may
involv
pharyngoconjunctiv
fever
caus
adenovirus
type
may
epidem
endem
among
children
summer
temper
climat
associ
inadequ
chlorin
filtrat
swim
pool
ocular
transmiss
also
associ
physician
offic
steril
hand
wash
inadequ
asymptomat
adenovir
infect
prolong
carrier
state
common
nonepidem
adenovir
infect
asymptomat
fact
adenovirus
discov
propens
latenc
adenoid
tissu
symptomat
infect
may
involv
part
respiratori
tract
gener
initi
upper
respiratori
epithelium
adenoviru
infect
result
necrosi
cell
airway
epithelia
may
caus
viremia
system
viru
dissemin
immunocompromis
person
bronchiol
interstiti
pneumon
mononuclear
cell
infiltr
part
inflammatori
process
lung
addit
lytic
infect
adenovirus
may
becom
latent
epitheli
lymphoid
cell
probabl
import
maintain
viru
popul
protect
adenoviru
infect
diseas
mainli
due
typespecif
neutral
antibodi
reinfect
mostli
asymptomat
may
occur
longliv
tcell
immun
respons
develop
infect
immunocompet
person
respons
recoveri
infect
also
tissu
patholog
chang
incub
period
adenoviru
infect
averag
day
usual
symptom
febril
cold
children
fever
may
high
longlast
pharyng
common
may
associ
fever
pharyng
exud
granular
appear
mucosa
anterior
cervic
adenopathi
similarli
streptococc
pharyng
frequent
complic
adenovir
cold
acut
otiti
media
occur
case
adenovirus
recov
case
pharyng
small
children
symptom
may
concurr
pharyngoconjunctiv
fever
syndrom
caus
mostli
adenoviru
type
character
conjunct
frequent
unilater
may
last
week
preauricular
adenopathi
cough
rhiniti
malais
fever
adenoviru
lri
mainli
bronchiti
pneumonia
may
repres
childhood
lri
temper
area
perman
lung
parenchym
damag
may
occur
especi
adenovir
infect
concurr
measl
clinic
manifest
epidem
adenovir
infect
militari
recruit
may
rang
cold
sever
pneumonia
typic
manifest
fever
pharyng
symptom
cough
chest
pain
headach
malais
overwhelm
pneumon
may
part
dissemin
adenovir
infect
newborn
infant
patient
immunodefici
includ
aid
howev
frequent
concomit
respiratori
pathogen
aid
patient
high
preval
asymptomat
adenoviru
infect
shed
doubt
causal
role
adenoviru
patient
adenovirus
detect
respiratori
ocular
ear
secret
clinic
correl
requir
asymptomat
viru
shed
common
isol
adenovirus
cell
cultur
identif
use
decad
direct
detect
viral
antigen
viral
dna
pcr
clinic
sampl
sensit
rapid
altern
adenovirus
replic
well
continu
cell
line
epitheli
origin
hela
adapt
grow
human
embryon
lung
fibroblast
cultur
caus
characterist
cpe
mainten
cultur
week
combin
blind
passag
may
increas
adenoviru
recoveri
inocul
cell
centrifug
shell
vial
format
follow
immunostain
may
shorten
detect
time
rapid
antigen
detect
immunochromatographi
around
sensit
comparison
cell
cultur
easili
use
pointofcar
diagnosi
adenoviru
howev
convent
realtim
pcr
current
accept
sensit
diagnost
method
posit
result
pcr
interpret
caution
given
propens
adenovirus
caus
latenc
quantit
realtim
pcr
also
use
monitor
viral
load
transplant
recipi
immunosuppress
patient
allow
appropri
intervent
initi
immunosuppress
regimen
adjust
sever
serolog
test
detect
antibodi
common
hexon
antigen
howev
clinic
util
restrict
present
routin
effect
antivir
treatment
adenoviru
infect
success
therapi
sever
adenovir
infect
immunocompromis
patient
iv
ribavirin
report
trifluridin
cidofovir
shown
antivir
effect
vitro
potenti
use
treatment
live
vaccin
consist
wildtyp
adenoviru
packag
enter
coat
capsul
induc
immun
ensur
enter
replic
without
infect
respiratori
tree
proper
steril
hand
wash
chlorin
prevent
adenoviru
spread
via
tonomet
hand
swim
pool
human
coronaviru
hcov
subtyp
coronavirus
identifi
human
identif
sever
acut
respiratori
syndrom
sar
coronaviru
led
renew
research
hcov
follow
novel
coronavirus
discov
investig
netherland
isol
distinct
hcov
subtyp
also
known
nl
nh
child
bronchiol
conjunct
agent
close
relat
coronaviru
subsequ
detect
children
adult
worldwid
second
novel
coronaviru
subtyp
detect
adult
pneumonia
hong
kong
basi
antigen
genet
studi
known
hcov
distribut
two
three
coronaviru
group
far
identifi
belong
group
sarscov
belong
group
ii
group
iii
contain
known
human
agent
avian
coronavirus
coronavirus
envelop
virus
distinct
virion
morpholog
display
wide
space
long
petalshap
spike
surfac
confer
viru
crownlik
appear
origin
name
corona
figur
viral
envelop
contain
long
helic
nucleocapsid
singl
positivestrand
rna
kb
size
largest
known
viralrna
genom
coronaviru
rna
synthesi
occur
cytoplasm
via
negativestrand
rna
intermedi
figur
viral
rna
cap
end
leader
sequenc
follow
utr
end
termin
utr
follow
poli
tail
orf
genom
rna
translat
polyprotein
process
yield
protein
form
transcriptasehelicas
complex
genom
rna
use
templat
synthes
negativesens
rna
turn
use
synthes
fulllength
genom
rna
subgenom
mrna
mrna
direct
translat
viral
structur
nonstructur
protein
progeni
virus
assembl
bud
vesicl
endoplasm
reticulum
golgi
apparatu
later
releas
exocytosi
viral
envelop
contain
structur
protein
spike
membran
e
envelop
case
group
ii
coronavirus
glycoprotein
contain
neutral
cell
epitop
function
cell
receptor
ligand
protein
embed
envelop
interact
n
nucleocapsid
protein
matur
addit
nucleocapsid
envelop
protein
replicas
protein
bind
metalloproteas
human
aminopeptidas
n
cell
surfac
entri
independ
enzymat
activ
receptor
bind
sialic
acid
present
glycoprotein
cell
surfac
interact
facilit
infect
like
sarscov
util
angiotensinconvert
enzym
cell
receptor
hcov
found
throughout
world
consid
second
frequent
caus
common
cold
account
averag
rate
ari
gener
popul
unit
state
howev
rate
may
quit
variabl
year
year
rang
year
peak
activ
caus
common
cold
variabl
frequenc
depend
mainli
detect
method
season
studi
hcov
infect
occur
mainli
winter
spring
month
summer
activ
also
document
caus
winter
outbreak
interv
temper
region
littl
known
preval
tropic
countri
data
frequenc
impact
infect
still
scarc
conveni
small
anim
model
studi
pathogenesi
hcov
human
natur
experiment
infect
sourc
inform
known
infect
airway
epitheli
cell
apic
surfac
receptor
constitut
express
exit
product
infect
cell
rout
ultrastructur
studi
nasal
epithelium
volunt
experiment
infect
reveal
epitheli
cell
damag
ciliari
loss
cytolysi
day
postinfect
unit
state
seroposit
rise
first
year
life
around
adult
seroposit
symptomat
reinfect
possibl
despit
presenc
antibodi
suggest
rapidli
wane
immun
respons
circul
close
relat
antigen
differ
virus
hcov
transmit
respiratori
rout
experiment
infect
volunt
shed
viru
approxim
day
begin
h
infect
approxim
time
onset
symptom
peak
symptom
occur
day
postinocul
usual
manifest
hcov
infect
typic
common
cold
sever
diseas
seen
young
elderli
immunocompromis
host
incub
period
tend
day
longer
hrv
cold
ill
durat
day
lowgrad
fever
may
occur
patient
addit
nasal
symptom
cough
sore
throat
occur
frequent
seriou
infect
lrt
caus
hcov
also
document
either
sporad
infant
pneumonia
immunocompromis
patient
previous
healthi
marin
corp
recruit
pneumonia
addit
recogn
associ
influenzalik
ill
frail
elderli
patient
seem
play
major
role
caus
lrti
children
children
younger
year
infect
germani
croup
also
associ
lrti
children
elderli
patient
underli
diseas
hcov
infect
also
associ
exacerb
asthma
chronic
bronchiti
recurr
wheez
children
similar
hrv
hcov
infect
frequent
recogn
associ
otiti
media
maxillari
sinus
children
adult
hcov
detect
rtpcr
middl
ear
effus
nasopharyng
aspir
children
acut
otiti
media
finland
nasal
swab
adult
acut
maxillari
sinus
studi
indic
respiratori
hcov
abl
reach
central
nervou
system
real
import
agent
caus
diseas
outsid
respiratori
tract
remain
determin
yet
laboratori
diagnosi
hcov
clinic
sampl
isol
cell
cultur
difficult
rtpcrbase
assay
hcov
util
primer
rel
conserv
region
genom
current
best
altern
viru
detect
recent
quantit
realtim
pcr
hcov
develop
sever
laboratori
provid
rapid
sensit
way
detect
determin
viral
load
potenti
applic
pathogenesi
studi
serolog
diagnosi
hcov
sensit
specif
limit
applic
case
manag
intranas
interferon
protect
experiment
infect
antivir
drug
therapi
current
avail
nonsar
hcov
consid
usual
selflimit
cours
infect
support
care
symptomat
relief
suffici
vaccin
current
avail
hcov
agent
sarscov
share
structur
featur
genom
organ
coronavirida
recognit
peculiar
coronaviru
morpholog
electron
microscopi
vero
cell
inocul
oropharyng
materi
patient
initi
clue
identif
agent
viral
genom
nt
length
orf
code
put
protein
known
sarscov
protein
increas
cellular
rna
degrad
thu
might
facilit
sarscov
replic
block
immun
respons
trimer
protein
form
peplom
bind
cell
receptor
main
target
neutral
antibodi
n
protein
sarscov
induc
apoptosi
host
cell
may
play
import
role
pathogenesi
sarscov
phylogenet
differ
previous
known
coronavirus
isol
differ
origin
rel
similar
genom
analysi
reveal
sarscov
neither
hostrang
mutant
recombin
previous
known
coronavirus
rather
independ
emerg
viru
sarscov
seem
evolv
anim
sarslik
viru
acquir
greater
fit
human
cours
outbreak
probabl
appear
nucleotid
delet
infect
ntermin
portion
spike
glycoprotein
bind
viru
receptor
identifi
metallopeptidas
homologu
trigger
phdepend
endocytosi
sarscov
spike
protein
also
bind
dendrit
cellspecif
ctype
lectin
grab
nonintegrin
dcsign
result
dendrit
cell
infect
agent
allow
sarscov
transport
suscept
target
cell
elsewher
upon
entri
sarscov
replic
cycl
probabl
similar
coronavirus
sarscov
zoonot
origin
horsesho
bat
seem
natur
reservoir
begin
outbreak
probabl
animaltohuman
interspeci
transmiss
involv
provid
sourc
agent
later
adapt
effici
humantohuman
transmiss
palm
civet
perhap
mammal
serv
amplif
host
interestingli
shortli
wildlif
trade
ban
impos
control
sar
outbreak
natur
acquir
human
case
sar
guangdong
sarscov
mainli
transmit
among
human
deposit
infect
droplet
aerosol
respiratori
epithelium
addit
transmiss
infrequ
first
day
ill
partli
low
viral
load
respiratori
secret
phase
excret
sarscov
sputa
stool
may
averag
day
symptom
onset
respect
transmiss
sarscov
among
healthcar
worker
patient
hospit
set
play
pivot
role
outbreak
propag
assist
intub
suction
manipul
ventilatori
apparatus
highrisk
activ
sarscov
may
persist
day
environment
surfac
day
diarrheal
stool
approxim
case
report
outbreak
fatal
rate
least
present
circul
sarscov
regist
mechan
sarscov
damag
cell
tissu
complet
understood
viru
evad
innat
immun
respons
defens
interfer
interferon
product
degrad
cell
mrna
modul
ubiquitin
pathway
cell
damag
occur
necrosi
apoptosi
syncytium
format
sarscov
detect
respiratori
tissu
use
immunohistochemistri
situ
hybrid
electron
microscopi
pneumocyt
well
apic
surfac
enterocyt
mark
inflammatori
infiltr
observ
intestin
pathogenesi
sarscovrel
diarrhea
remain
larg
unknown
pulmonari
tissu
show
diffus
alveolar
damag
mix
infiltr
lung
edema
hyalin
membran
abund
macrophag
alveoli
interstitium
syncytia
format
higher
viral
load
sarscov
detect
lrt
upper
airway
besid
respiratori
secret
stool
sarscov
detect
urin
patient
effect
sarscov
infect
immun
system
highlight
pronounc
tcell
lymphopenia
elev
sever
inflammatori
cytokin
chemokin
observ
patient
sinc
immunolog
marker
peripher
blood
may
reflect
happen
microenviron
lung
pathogen
import
find
clear
seroconvers
document
patient
around
day
rise
igg
titer
correl
decreas
viral
load
paradox
clinic
worsen
also
occur
phase
suggest
rather
uncheck
viral
replic
immunopatholog
factor
may
respons
lung
lesion
incub
period
sar
day
initi
clinic
symptom
sign
system
symptom
fever
chill
myalgia
malais
respiratori
symptom
appear
day
later
frequent
nonproduct
cough
dyspnea
chest
pain
headach
sore
throat
diarrhea
vomit
may
occur
chest
radiogram
frequent
reveal
infiltr
consist
viral
pneumon
consist
mostli
consolid
groundglass
opacif
fever
gener
subsid
h
one
two
relaps
within
day
may
observ
wateri
diarrhea
averag
six
evacu
per
day
common
radiolog
worsen
pulmonari
lesion
seen
admiss
occur
develop
diffus
groundglass
chang
frequent
herald
develop
acut
respiratori
distress
syndrom
ard
hypoxemia
note
approxim
half
patient
around
day
onset
symptom
high
proport
admit
intens
care
unit
icu
especi
older
male
requir
mechan
ventil
around
day
prognosi
relat
level
viral
replic
tissu
patient
high
viral
load
serum
nasopharyng
aspir
fece
tend
poor
clinic
outcom
old
age
sever
underli
diseas
identifi
predictor
poor
outcom
fatal
rate
base
case
admit
hospit
patient
younger
year
older
year
abil
grow
sarscov
vero
cell
cultur
critic
identifi
agent
sarscov
recov
isol
respiratori
secret
fece
urin
procedur
done
biosafeti
level
laboratori
avail
hospit
world
although
use
earli
diagnosi
seroconvers
determin
ifa
eia
remain
gold
standard
confirm
sar
diagnosi
igg
seroconvers
detect
patient
around
day
rapid
diagnosi
antigen
detect
feasibl
less
sensit
rtpcr
realtim
quantit
rtpcr
nasopharyng
aspir
method
choic
around
sensit
low
viral
load
upper
respiratori
tract
first
day
ill
sarscov
detect
rtpcr
nasopharyng
aspir
onethird
patient
present
twothird
day
rtpcr
may
posit
sarscov
stool
much
patient
day
urin
sampl
day
sensit
rtpcr
could
increas
test
multipl
specimen
includ
nasopharyng
serum
fecal
sampl
main
compon
treatment
sar
patient
support
therapi
chiefli
manag
hypoxemia
ard
sarscov
modestli
suscept
ribavirin
vitro
therapeut
dose
difficult
achiev
clinic
mani
potenti
antivir
compound
evalu
vitro
test
anim
model
even
fewer
patient
interferon
leukocyt
ifn
ifn
proteas
inhibitor
consist
activ
vitro
may
consid
treatment
analogu
antivir
peptid
protein
small
interf
rna
sirna
also
effect
vitro
pegyl
shown
use
monkey
model
convalesc
plasma
also
test
treatment
sar
patient
reduc
frequenc
poor
outcom
given
day
ill
imposs
predict
whether
natur
reemerg
sarscov
would
caus
global
outbreak
present
sarscov
vaccin
avail
human
use
nevertheless
vaccin
agent
would
relev
highrisk
individu
worker
laboratori
hospit
game
anim
farm
therefor
consider
effort
direct
develop
vaccin
shown
sarscov
protein
express
chimer
parainfluenza
viru
vaccinia
viru
well
spike
protein
encod
dnainduc
neutral
antibodi
protect
experiment
anim
challeng
live
viru
sever
type
vaccin
candid
develop
includ
inactiv
viru
subunit
vaccin
viruslik
particl
vlp
dna
vaccin
heterolog
express
system
vaccin
deriv
sarscov
revers
genet
agent
human
bocaviru
hbov
recent
discov
mean
eleg
metagenom
approach
detect
sampl
children
ari
studi
around
world
hbov
describ
screen
pool
respiratori
clinic
sampl
test
neg
viral
agent
dna
extract
gradient
purifi
virusenrich
fraction
pool
clinic
sampl
randomli
amplifi
pcr
clone
sequenc
reveal
presenc
previous
unknown
parvoviru
bioinformat
analysi
sequenc
reveal
novel
member
famili
parvovirida
provision
classifi
sequenc
homolog
genom
organ
genu
bocaviru
alreadi
includ
two
virus
bovin
parvoviru
canin
minut
viru
hbov
virion
consist
small
nonenvelop
icosahedr
particl
singlestrand
dna
genom
approxim
nt
organ
way
similar
known
bocavirus
three
orf
two
encod
nonstructur
protein
third
nest
two
capsid
protein
figur
like
viral
polymeras
function
still
unknown
hbov
replic
cycl
studi
like
similar
autonom
parvovirida
two
genet
distinct
cluster
detect
degre
variabl
higher
gene
capsid
protein
hbov
propag
cell
cultur
hamper
cell
biolog
studi
product
viru
stock
pathogenesi
studi
hbov
circul
worldwid
preval
studi
done
mostli
pcr
respiratori
sampl
children
shown
detect
rate
depend
region
studi
conduct
sensit
assay
far
clear
hbov
season
fact
hbov
may
persist
long
time
primari
infect
posit
pcr
result
may
found
healthi
carrier
asymptomat
persist
may
serious
affect
incid
estim
seropreval
children
unit
state
use
vlp
antigen
reveal
children
older
year
alreadi
expos
hbov
studi
report
hbov
detect
age
group
children
younger
year
repres
vast
major
patient
investig
date
